Search

Your search keyword '"Pearson, Andrew D.J."' showing total 191 results
Start Over Author "Pearson, Andrew D.J."
191 results on '"Pearson, Andrew D.J."'

1. Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration

Author

Pearson, Andrew D.J., Federico, Sara, Gatz, Susanne A., Ortiz, Michael, Lesa, Giovanni, Scobie, Nicole, Gounaris, Ioannis, Weiner, Susan L., Weigel, Brenda, Unger, T.J., Stewart, Elizabeth, Smith, Malcolm, Slotkin, Emily K., Reaman, Gregory, Pappo, Alberto, Nysom, Karsten, Norga, Koen, McDonough, Joe, Marshall, Lynley V., Ludwinski, Donna, Ligas, Franca, Karres, Dominik, Kool, Marcel, Horner, Thierry J., Henssen, Anton, Heenen, Delphine, Hawkins, Douglas S., Gore, Lia, Bender, Julia Glade, Galluzzo, Sara, Fox, Elizabeth, de Rojas, Teresa, Davies, Barry R., Chakrabarti, Jayeta, Carmichael, Juliet, Bradford, Diana, Blanc, Patricia, Bernardi, Ronald, Benchetrit, Sylvie, Akindele, Korede, and Vassal, Gilles

Published
2023
Full Text
View/download PDF

3. Combination Early-Phase Trials of Anticancer Agents in Children and Adolescents

Author

Moreno, Lucas, primary, DuBois, Steven G., additional, Glade Bender, Julia, additional, Mauguen, Audrey, additional, Bird, Nick, additional, Buenger, Vickie, additional, Casanova, Michela, additional, Doz, François, additional, Fox, Elizabeth, additional, Gore, Lia, additional, Hawkins, Douglas S., additional, Izraeli, Shai, additional, Jones, David T.W., additional, Kearns, Pamela R., additional, Molenaar, Jan J., additional, Nysom, Karsten, additional, Pfister, Stefan, additional, Reaman, Gregory, additional, Smith, Malcolm, additional, Weigel, Brenda, additional, Vassal, Gilles, additional, Zwaan, Christian Michel, additional, Paoletti, Xavier, additional, Iasonos, Alexia, additional, and Pearson, Andrew D.J., additional

Published
2023
Full Text
View/download PDF

5. Rescuing Drugs That are Discontinued in Adult Oncology Development for the Benefit of Children and Adolescents With Cancer – An ACCELERATE Multistakeholder Consensus.

Author

de Rojas, Teresa, Chiodin, Davy, Pearson, Andrew D.J., Heenen, Delphine, Adamson, Peter, Caron, Hubert, and Vassal, Gilles

Subjects
DRUG repositioning, ADULT development, CHILD development, CHILDHOOD cancer, DRUG standards, YOUNG adults, CHILD patients
Abstract

Better therapies for childhood cancer remain an unmet need to improve the dismal prognosis of certain malignancies and to reduce the burden of toxicity. Rescuing discontinued or shelved drugs for children, adolescents, and young adults is a strategy to identify new uses for approved or investigational medicines outside the scope of their original medical indication. Our proposed multistakeholder consensus focuses on the development of innovative, patent‐protected targeted agents, sourced from previously shelved or discontinued programs that have the potential to provide significant benefit to underserved patient populations, with unmet medical needs. There are several challenges to continuing/rescuing drugs for pediatric oncology development, which include the lack of information for decision making, corporate strategy considerations underlying the decision to invest in pediatric development, and the contracting and technology transfer complexities required to enable divestment and subsequent development. The multistakeholder approach for drug development has the advantage of conveying a consensus among academia, patient advocates, and importantly industry itself. We propose three areas of action to facilitate rescuing potentially beneficial drugs for children and adolescents with cancer: (i) initiatives to provide information to companies considering developing these drugs and a standards framework; (ii) incentives both in Europe and in the United States to encourage companies to develop pediatric‐only drugs, with the reform of the EU Pharmaceutical Legislation posing an important opportunity; and (iii) communication of the issues to all stakeholders. Ultimately, this will benefit children and adolescents with cancer. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Supplementary Table 1 from A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study

Author

Moreno, Lucas, primary, Marshall, Lynley V., primary, Pearson, Andrew D.J., primary, Morland, Bruce, primary, Elliott, Martin, primary, Campbell-Hewson, Quentin, primary, Makin, Guy, primary, Halford, Sarah E.R., primary, Acton, Gary, primary, Ross, Philip, primary, Kazmi-Stokes, Shamim, primary, Lock, Victoria, primary, Rodriguez, Ana, primary, Lyons, John F., primary, Boddy, Alan V., primary, Griffin, Melanie J., primary, Yule, Murray, primary, and Hargrave, Darren, primary

Published
2023
Full Text
View/download PDF

7. Pub fees email yes from A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors

Author

Geoerger, Birgit, primary, Bourdeaut, Franck, primary, DuBois, Steven G., primary, Fischer, Matthias, primary, Geller, James I., primary, Gottardo, Nicholas G., primary, Marabelle, Aurélien, primary, Pearson, Andrew D.J., primary, Modak, Shakeel, primary, Cash, Thomas, primary, Robinson, Giles W., primary, Motta, Marlyane, primary, Matano, Alessandro, primary, Bhansali, Suraj G., primary, Dobson, Jason R., primary, Parasuraman, Sudha, primary, and Chi, Susan N., primary

Published
2023
Full Text
View/download PDF

8. Data from MRI Imaging of the Hemodynamic Vasculature of Neuroblastoma Predicts Response to Antiangiogenic Treatment

Author

Zormpas-Petridis, Konstantinos, primary, Jerome, Neil P., primary, Blackledge, Matthew D., primary, Carceller, Fernando, primary, Poon, Evon, primary, Clarke, Matthew, primary, McErlean, Ciara M., primary, Barone, Giuseppe, primary, Koers, Alexander, primary, Vaidya, Sucheta J., primary, Marshall, Lynley V., primary, Pearson, Andrew D.J., primary, Moreno, Lucas, primary, Anderson, John, primary, Sebire, Neil, primary, McHugh, Kieran, primary, Koh, Dow-Mu, primary, Yuan, Yinyin, primary, Chesler, Louis, primary, Robinson, Simon P., primary, and Jamin, Yann, primary

Published
2023
Full Text
View/download PDF

9. Data from Noninvasive MRI Native T1 Mapping Detects Response to MYCN-targeted Therapies in the Th-MYCN Model of Neuroblastoma

Author

Zormpas-Petridis, Konstantinos, primary, Poon, Evon, primary, Clarke, Matthew, primary, Jerome, Neil P., primary, Boult, Jessica K.R., primary, Blackledge, Matthew D., primary, Carceller, Fernando, primary, Koers, Alexander, primary, Barone, Giuseppe, primary, Pearson, Andrew D.J., primary, Moreno, Lucas, primary, Anderson, John, primary, Sebire, Neil, primary, McHugh, Kieran, primary, Koh, Dow-Mu, primary, Chesler, Louis, primary, Yuan, Yinyin, primary, Robinson, Simon P., primary, and Jamin, Yann, primary

Published
2023
Full Text
View/download PDF

11. Table S3 from A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation–Positive Solid Tumors

Author

Kieran, Mark W., primary, Geoerger, Birgit, primary, Dunkel, Ira J., primary, Broniscer, Alberto, primary, Hargrave, Darren, primary, Hingorani, Pooja, primary, Aerts, Isabelle, primary, Bertozzi, Anne-Isabelle, primary, Cohen, Kenneth J., primary, Hummel, Trent R., primary, Shen, Violet, primary, Bouffet, Eric, primary, Pratilas, Christine A., primary, Pearson, Andrew D.J., primary, Tseng, Lillian, primary, Nebot, Noelia, primary, Green, Steven, primary, Russo, Mark W., primary, and Whitlock, James A., primary

Published
2023
Full Text
View/download PDF

12. Supplementary Figure 1 from A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study

Author

Moreno, Lucas, primary, Marshall, Lynley V., primary, Pearson, Andrew D.J., primary, Morland, Bruce, primary, Elliott, Martin, primary, Campbell-Hewson, Quentin, primary, Makin, Guy, primary, Halford, Sarah E.R., primary, Acton, Gary, primary, Ross, Philip, primary, Kazmi-Stokes, Shamim, primary, Lock, Victoria, primary, Rodriguez, Ana, primary, Lyons, John F., primary, Boddy, Alan V., primary, Griffin, Melanie J., primary, Yule, Murray, primary, and Hargrave, Darren, primary

Published
2023
Full Text
View/download PDF

13. Supplementary Data from EGFRvIII Deletion Mutations in Pediatric High-Grade Glioma and Response to Targeted Therapy in Pediatric Glioma Cell Lines

Author

Bax, Dorine A., primary, Gaspar, Nathalie, primary, Little, Suzanne E., primary, Marshall, Lynley, primary, Perryman, Lara, primary, Regairaz, Marie, primary, Viana-Pereira, Marta, primary, Vuononvirta, Raisa, primary, Sharp, Swee Y., primary, Reis-Filho, Jorge S., primary, Stávale, João N., primary, Al-Sarraj, Safa, primary, Reis, Rui M., primary, Vassal, Gilles, primary, Pearson, Andrew D.J., primary, Hargrave, Darren, primary, Ellison, David W., primary, Workman, Paul, primary, and Jones, Chris, primary

Published
2023
Full Text
View/download PDF

14. Supplementary Data from Noninvasive MRI Native T1 Mapping Detects Response to MYCN-targeted Therapies in the Th-MYCN Model of Neuroblastoma

Author

Zormpas-Petridis, Konstantinos, primary, Poon, Evon, primary, Clarke, Matthew, primary, Jerome, Neil P., primary, Boult, Jessica K.R., primary, Blackledge, Matthew D., primary, Carceller, Fernando, primary, Koers, Alexander, primary, Barone, Giuseppe, primary, Pearson, Andrew D.J., primary, Moreno, Lucas, primary, Anderson, John, primary, Sebire, Neil, primary, McHugh, Kieran, primary, Koh, Dow-Mu, primary, Chesler, Louis, primary, Yuan, Yinyin, primary, Robinson, Simon P., primary, and Jamin, Yann, primary

Published
2023
Full Text
View/download PDF

15. Supplementary Data from MRI Imaging of the Hemodynamic Vasculature of Neuroblastoma Predicts Response to Antiangiogenic Treatment

Author

Zormpas-Petridis, Konstantinos, primary, Jerome, Neil P., primary, Blackledge, Matthew D., primary, Carceller, Fernando, primary, Poon, Evon, primary, Clarke, Matthew, primary, McErlean, Ciara M., primary, Barone, Giuseppe, primary, Koers, Alexander, primary, Vaidya, Sucheta J., primary, Marshall, Lynley V., primary, Pearson, Andrew D.J., primary, Moreno, Lucas, primary, Anderson, John, primary, Sebire, Neil, primary, McHugh, Kieran, primary, Koh, Dow-Mu, primary, Yuan, Yinyin, primary, Chesler, Louis, primary, Robinson, Simon P., primary, and Jamin, Yann, primary

Published
2023
Full Text
View/download PDF

18. Combination Early-Phase Trials of Anticancer Agents in Children and Adolescents

Author

Moreno, Lucas, Dubois, Steven G., Glade Bender, Julia, Mauguen, Audrey, Bird, Nick, Buenger, Vickie, Casanova, Michela, Doz, François, Fox, Elizabeth, Gore, Lia, Hawkins, Douglas S., Izraeli, Shai, Jones, David T.W., Kearns, Pamela R., Molenaar, Jan J., Nysom, Karsten, Pfister, Stefan, Reaman, Gregory, Smith, Malcolm, Weigel, Brenda, Vassal, Gilles, Zwaan, Christian Michel, Paoletti, Xavier, Iasonos, Alexia, Pearson, Andrew D.J., Moreno, Lucas, Dubois, Steven G., Glade Bender, Julia, Mauguen, Audrey, Bird, Nick, Buenger, Vickie, Casanova, Michela, Doz, François, Fox, Elizabeth, Gore, Lia, Hawkins, Douglas S., Izraeli, Shai, Jones, David T.W., Kearns, Pamela R., Molenaar, Jan J., Nysom, Karsten, Pfister, Stefan, Reaman, Gregory, Smith, Malcolm, Weigel, Brenda, Vassal, Gilles, Zwaan, Christian Michel, Paoletti, Xavier, Iasonos, Alexia, and Pearson, Andrew D.J.

Abstract

PURPOSEThere is an increasing need to evaluate innovative drugs for childhood cancer using combination strategies. Strong biological rationale and clinical experience suggest that multiple agents will be more efficacious than monotherapy for most diseases and may overcome resistance mechanisms and increase synergy. The process to evaluate these combination trials needs to maximize efficiency and should be agreed by all stakeholders.METHODSAfter a review of existing combination trial methodologies, regulatory requirements, and current results, a consensus among stakeholders was achieved.RESULTSCombinations of anticancer therapies should be developed on the basis of mechanism of action and robust preclinical evaluation, and may include data from adult clinical trials. The general principle for combination early-phase studies is that, when possible, clinical trials should be dose- and schedule-confirmatory rather than dose-exploratory, and every effort should be made to optimize doses early. Efficient early-phase combination trials should be seamless, including dose confirmation and randomized expansion. Dose evaluation designs for combinations depend on the extent of previous knowledge. If not previously evaluated, limited evaluation of monotherapy should be included in the same clinical trial as the combination. Randomized evaluation of a new agent plus standard therapy versus standard therapy is the most effective approach to isolate the effect and toxicity of the novel agent. Platform trials may be valuable in the evaluation of combination studies. Patient advocates and regulators should be engaged with investigators early in a proposed clinical development pathway and trial design must consider regulatory requirements.CONCLUSIONAn optimized, agreed approach to the design and evaluation of early-phase pediatric combination trials will accelerate drug development and benefit all stakeholders, most importantly children and adolescents with cancer.

Published
2023

19. Prognostic factors of overall survival in children and adolescents enrolled in dose-finding trials in Europe: An Innovative Therapies for Children with Cancer study

Author

Carceller, Fernando, Bautista, Francisco J., Jiménez, Irene, Hladun-Álvaro, Raquel, Giraud, Cécile, Bergamaschi, Luca, Dandapani, Madhumita, Aerts, Isabelle, Doz, François, Frappaz, Didier, Casanova, Michela, Morland, Bruce, Hargrave, Darren R., Marshall, Lynley V., Vassal, Gilles, Pearson, Andrew D.J., Geoerger, Birgit, and Moreno, Lucas

Published
2016
Full Text
View/download PDF

21. Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration

Author

Pearson, Andrew D.J., Gaspar, Nathalie, Janeway, Katherine, Campbell-Hewson, Quentin, Lawlor, Elizabeth R., Copland, Chris, Karres, Dominik, Norga, Koenraad, Benzaghou, Fawzi, Weiner, Susan, Weigel, Brenda, Weiss, Aaron R., Strauss, Sandra J., Smith, Malcolm, Setty, Bhuvana A., Seibel, Nita, Scobie, Nicole, Pappo, Alberto, Okpara, Chinyere E., Nysom, Karsten, McDonough, Joe, Marshall, Lynley V., Ludwinski, Donna, Ligas, Franca, Lesa, Giovanni, Knudsen, Steen, Kauh, John, Hsieh, Antony, Heenen, Delphine, Hawkins, Douglas S., Graham, Ann, Garmey, Edward, DuBois, Steven G., Fox, Elizabeth, Donoghue, Martha, de Rojas, Teresa, Chung, John, Casanova, Michela, Brennan, Bernadette, Bishop, Michael, Buenger, Vickie, Reaman, Gregory, and Vassal, Gilles

Subjects
Adult, Osteosarcoma, Adolescent, United States Food and Drug Administration, Humans, Bone Neoplasms, Human medicine, Prospective Studies, Neoplasm Recurrence, Local, Child, United States, Retrospective Studies
Abstract

The eighth Paediatric Strategy Forum focused on multi-targeted kinase inhibitors (mTKIs) in osteosarcoma and Ewing sarcoma. The development of curative, innovative products in these tumours is a high priority and addresses unmet needs in children, adolescents and adults. Despite clinical and investigational use of mTKIs, efficacy in patients with bone tumours has not been definitively demonstrated. Randomised studies, currently being planned or in progress, in front-line and relapse settings will inform the further development of this class of product. It is crucial that these are rapidly initiated to generate robust data to support international collaborative efforts. The experience to date has generally indicated that the safety profile of mTKIs as monotherapy, and in combination with chemotherapy or other targeted therapy, is consistent with that of adults and that toxicity is manageable. Increasing understanding of relevant predictive biomarkers and tumour biology is absolutely critical to further develop this class of products. Biospecimen samples for correlative studies and biomarker development should be shared, and a joint academic-industry consortium created. This would result in an integrated collection of serial tumour tissues and a systematic retrospective and prospective analyses of these samples to ensure robust assessment of biologic effect of mTKIs. To support access for children to benefit from these novel therapies, clinical trials should be designed with sufficient scientific rationale to support regulatory and payer requirements. To achieve this, early dialogue between academia, industry, regulators, and patient advocates is essential. Evaluating feasibility of combination strategies and then undertaking a randomised trial in the same protocol accelerates drug development. Where possible, clinical trials and development should include children, adolescents, and adults less than 40 years. To respond to emerging science, in approximately 12 months, a multi-stakeholder group will meet and review available data to determine future directions and priorities.

Published
2022

22. The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma

Author

Berry, Teeara, Luther, William, Bhatnagar, Namrata, Jamin, Yann, Poon, Evon, Sanda, Takaomi, Pei, Desheng, Sharma, Bandana, Vetharoy, Winston R., Hallsworth, Albert, Ahmad, Zai, Barker, Karen, Moreau, Lisa, Webber, Hannah, Wang, Wenchao, Liu, Qingsong, Perez-Atayde, Antonio, Rodig, Scott, Cheung, Nai-Kong, Raynaud, Florence, Hallberg, Bengt, Robinson, Simon P., Gray, Nathanael S., Pearson, Andrew D.J., Eccles, Suzanne A., Chesler, Louis, and George, Rani E.

Published
2012
Full Text
View/download PDF

24. ACCELERATE – Five years accelerating cancer drug development for children and adolescents

Author

Pearson, Andrew D.J., primary, Weiner, Susan L., additional, Adamson, Peter C., additional, Karres, Dominik, additional, Reaman, Gregory, additional, Rousseau, Raphaël, additional, Blanc, Patricia, additional, Norga, Koen, additional, Skolnik, Jeffrey, additional, Kearns, Pam, additional, Scobie, Nicole, additional, Barry, Elly, additional, Marshall, Lynley V., additional, Knox, Leona, additional, Caron, Hubert, additional, Wariabharaj, Darshan, additional, Pappo, Alberto, additional, DuBois, Steven G., additional, Gore, Lia, additional, Kieran, Mark, additional, Weigel, Brenda, additional, Fox, Elizabeth, additional, Nysom, Karsten, additional, de Rojas, Teresa, additional, and Vassal, Gilles, additional

Published
2022
Full Text
View/download PDF

28. Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies

Author

Pearson, Andrew D.J., primary, Barry, Elly, additional, Mossé, Yael P., additional, Ligas, Franca, additional, Bird, Nick, additional, de Rojas, Teresa, additional, Zimmerman, Zachary F., additional, Wilner, Keith, additional, Woessmann, Willi, additional, Weiner, Susan, additional, Weigel, Brenda, additional, Venkatramani, Rajkumar, additional, Valteau, Dominique, additional, Trahair, Toby, additional, Smith, Malcolm, additional, Singh, Sonia, additional, Selvaggi, Giovanni, additional, Scobie, Nicole, additional, Schleiermacher, Gudrun, additional, Richardson, Nicholas, additional, Park, Julie, additional, Nysom, Karsten, additional, Norga, Koen, additional, Merino, Margret, additional, McDonough, Joe, additional, Matloub, Yousif, additional, Marshall, Lynley V., additional, Lowe, Eric, additional, Lesa, Giovanni, additional, Irwin, Meredith, additional, Karres, Dominik, additional, Gajjar, Amar, additional, Doz, François, additional, Fox, Elizabeth, additional, DuBois, Steven G., additional, Donoghue, Martha, additional, Casanova, Michela, additional, Caron, Hubert, additional, Buenger, Vickie, additional, Bradford, Diana, additional, Blanc, Patricia, additional, Barone, Amy, additional, Reaman, Gregory, additional, and Vassal, Gilles, additional

Published
2021
Full Text
View/download PDF

29. Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies

Author

Geoerger, Birgit, primary, Morland, Bruce, additional, Jiménez, Irene, additional, Frappaz, Didier, additional, Pearson, Andrew D.J., additional, Vassal, Gilles, additional, Maeda, Patricia, additional, Kincaide, Jasmine, additional, Mueller, Udo, additional, Schlief, Sarah, additional, Teufel, Michael, additional, Ploeger, Bart A., additional, Cleton, Adriaan, additional, Agostinho, Andrea C., additional, and Marshall, Lynley V., additional

Published
2021
Full Text
View/download PDF

34. A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high‐risk neuroblastoma: An International Neuroblastoma Risk Group project

Author

Moreno, Lucas, primary, Guo, Dongjing, additional, Irwin, Meredith S., additional, Berthold, Frank, additional, Hogarty, Michael, additional, Kamijo, Takehiko, additional, Morgenstern, Daniel, additional, Pasqualini, Claudia, additional, Ash, Shifra, additional, Potschger, Ulrike, additional, Ladenstein, Ruth, additional, Valteau‐Couanet, Dominique, additional, Cohn, Susan L., additional, Pearson, Andrew D.J., additional, and London, Wendy B., additional

Published
2020
Full Text
View/download PDF

35. Reply to K. Beiske et al

Author

Sokol, Elizabeth, primary, Desai, Ami V., additional, Applebaum, Mark A., additional, Valteau-Couanet, Dominique, additional, Park, Julie R., additional, Pearson, Andrew D.J., additional, Schleiermacher, Gudrun, additional, Irwin, Meredith S., additional, Hogarty, Michael, additional, Naranjo, Arlene, additional, Volchenboum, Samuel, additional, Cohn, Susan L., additional, and London, Wendy B., additional

Published
2020
Full Text
View/download PDF

36. Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma

Author

Moreno, Lucas, primary, Barone, Giuseppe, additional, DuBois, Steven G., additional, Molenaar, Jan, additional, Fischer, Matthias, additional, Schulte, Johannes, additional, Eggert, Angelika, additional, Schleiermacher, Gudrun, additional, Speleman, Frank, additional, Chesler, Louis, additional, Geoerger, Birgit, additional, Hogarty, Michael D., additional, Irwin, Meredith S., additional, Bird, Nick, additional, Blanchard, Guy B., additional, Buckland, Sean, additional, Caron, Hubert, additional, Davis, Susan, additional, De Wilde, Bram, additional, Deubzer, Hedwig E., additional, Dolman, Emmy, additional, Eilers, Martin, additional, George, Rani E., additional, George, Sally, additional, Jaroslav, Štěrba, additional, Maris, John M., additional, Marshall, Lynley, additional, Merchant, Melinda, additional, Mortimer, Peter, additional, Owens, Cormac, additional, Philpott, Anna, additional, Poon, Evon, additional, Shay, Jerry W., additional, Tonelli, Roberto, additional, Valteau-Couanet, Dominique, additional, Vassal, Gilles, additional, Park, Julie R., additional, and Pearson, Andrew D.J., additional

Published
2020
Full Text
View/download PDF

37. Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents

Author

Pearson, Andrew D.J., primary, Zwaan, C.Michel, additional, Kolb, E.Anders, additional, Karres, Dominik, additional, Guillot, Julie, additional, Kim, Su Young, additional, Marshall, Lynley, additional, Tasian, Sarah K., additional, Smith, Malcolm, additional, Cooper, Todd, additional, Adamson, Peter C., additional, Barry, Elly, additional, Benettaib, Bouchra, additional, Binlich, Florence, additional, Borgman, Anne, additional, Brivio, Erica, additional, Capdeville, Renaud, additional, Delgado, David, additional, Faller, Douglas, additional, Fogelstrand, Linda, additional, Fraenkel, Paula Goodman, additional, Hasle, Henrik, additional, Heenen, Delphine, additional, Kaspers, Gertjan, additional, Kieran, Mark, additional, Klusmann, Jan-Henning, additional, Lesa, Giovanni, additional, Ligas, Franca, additional, Mappa, Silvia, additional, Mohamed, Hesham, additional, Moore, Andrew, additional, Morris, Joan, additional, Nottage, Kerri, additional, Reinhardt, Dirk, additional, Scobie, Nicole, additional, Simko, Stephen, additional, Winkler, Thomas, additional, Norga, Koen, additional, Reaman, Gregory, additional, and Vassal, Gilles, additional

Published
2020
Full Text
View/download PDF

38. Noninvasive MRI Native T1 Mapping Detects Response to MYCN-targeted Therapies in the Th-MYCN Model of Neuroblastoma

Author

Zormpas-Petridis, Konstantinos, primary, Poon, Evon, additional, Clarke, Matthew, additional, Jerome, Neil P., additional, Boult, Jessica K.R., additional, Blackledge, Matthew D., additional, Carceller, Fernando, additional, Koers, Alexander, additional, Barone, Giuseppe, additional, Pearson, Andrew D.J., additional, Moreno, Lucas, additional, Anderson, John, additional, Sebire, Neil, additional, McHugh, Kieran, additional, Koh, Dow-Mu, additional, Chesler, Louis, additional, Yuan, Yinyin, additional, Robinson, Simon P., additional, and Jamin, Yann, additional

Published
2020
Full Text
View/download PDF

39. Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project

Author

Sokol, Elizabeth, primary, Desai, Ami V., additional, Applebaum, Mark A., additional, Valteau-Couanet, Dominique, additional, Park, Julie R., additional, Pearson, Andrew D.J., additional, Schleiermacher, Gudrun, additional, Irwin, Meredith S., additional, Hogarty, Michael, additional, Naranjo, Arlene, additional, Volchenboum, Samuel, additional, Cohn, Susan L., additional, and London, Wendy B., additional

Published
2020
Full Text
View/download PDF

41. ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients

Author

Pearson, Andrew D.J., primary, Rossig, Claudia, additional, Lesa, Giovanni, additional, Diede, Scott J., additional, Weiner, Susan, additional, Anderson, John, additional, Gray, Juliet, additional, Geoerger, Birgit, additional, Minard-Colin, Veronique, additional, Marshall, Lynley V., additional, Smith, Malcolm, additional, Sondel, Paul, additional, Bajars, Marcis, additional, Baldazzi, Claudia, additional, Barry, Elly, additional, Blackman, Sam, additional, Blanc, Patricia, additional, Capdeville, Renaud, additional, Caron, Hubert, additional, Cole, Peter D., additional, Jiménez, Jorge Camarero, additional, Demolis, Pierre, additional, Donoghue, Martha, additional, Elgadi, Mabrouck, additional, Gajewski, Thomas, additional, Galluzzo, Sara, additional, Ilaria, Robert, additional, Jenkner, Alessandro, additional, Karres, Dominik, additional, Kieran, Mark, additional, Ligas, Franca, additional, Lowy, Israel, additional, Meyers, Michael, additional, Oprea, Corina, additional, Peddareddigari, Vijay G.R., additional, Sterba, Jaroslav, additional, Stockman, Paul K., additional, Suenaert, Peter, additional, Tabori, Uri, additional, van Tilburg, Cornelis, additional, Yancey, Todd, additional, Weigel, Brenda, additional, Norga, Koenraad, additional, Reaman, Gregory, additional, and Vassal, Gilles, additional

Published
2020
Full Text
View/download PDF

42. A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation–Positive Solid Tumors

Author

Kieran, Mark W., primary, Geoerger, Birgit, additional, Dunkel, Ira J., additional, Broniscer, Alberto, additional, Hargrave, Darren, additional, Hingorani, Pooja, additional, Aerts, Isabelle, additional, Bertozzi, Anne-Isabelle, additional, Cohen, Kenneth J., additional, Hummel, Trent R., additional, Shen, Violet, additional, Bouffet, Eric, additional, Pratilas, Christine A., additional, Pearson, Andrew D.J., additional, Tseng, Lillian, additional, Nebot, Noelia, additional, Green, Steven, additional, Russo, Mark W., additional, and Whitlock, James A., additional

Published
2019
Full Text
View/download PDF

44. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma

Author

Bown, Nick, Cotterill, Simon, Lastowska, Maria, O'Neill, Seamus, Pearson, Andrew D.J., Plantaz, Dominique, Meddeb, Mounira, Danglot, Gisele, Brinkschmidt, Christian, Christiansen, Holger, Laureys, Genevieve, and Speleman, Frank

Subjects
Neuroblastoma -- Genetic aspects, Chromosome abnormalities -- Health aspects
Abstract

A gain of chromosome arm 17q appears to be associated with a poor prognosis in children with neuroblastoma. This occurs when the long arm of chromosome 17 becomes attached to another chromosome. Researchers used cytogenetic analysis to study chromosome 17 in tumor samples from 313 neuroblastoma patients. A gain of chromosome arm 17q occurred in 54% of the tumors. Patients with this chromosome abnormality had a five-year survival rate of 31%, compared to a five-year survival rate of 86% in those without the abnormality.

Published
1999

48. Large cell neuroblastoma

Author

Tornoczky, Tamas, Kalman, Endre, Kajtar, Pal G., Nyari, Tibor, Pearson, Andrew D.J., Tweddle, Deborah A., Board, Julian, and Shimada, Hiroyuki

Subjects
Neuroblastoma -- Surveys, Neuroblastoma -- Care and treatment, Health
Published
2004

Catalog

Books, media, physical & digital resources
See catalog results